Comparative Pharmacology
Head-to-head clinical analysis: CIPRO HC versus COR OTICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO HC versus COR OTICIN.
CIPRO HC vs COR-OTICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription; hydrocortisone suppresses inflammation via glucocorticoid receptor activation.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Instill 3 drops into the affected ear(s) twice daily (morning and evening) for 7 days.
1-2 drops in each affected ear twice daily for 7 days.
None Documented
None Documented
Ciprofloxacin: 4-6 hours (prolonged to 6-9 hours in elderly or renal impairment). Hydrocortisone: 1-2 hours.
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Ciprofloxacin: ~50-70% excreted renally as unchanged drug, ~15% as metabolites; ~20-30% eliminated via biliary/fecal route. Hydrocortisone: metabolized hepatically, renal excretion of metabolites.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Category C
Category C
Antibiotic/Corticosteroid Combination (Otic)
Topical Corticosteroid + Antibiotic